Strong associations of some pharmacokinetic/pharmacodynamic gene variants, e.g., CYP2D6 and DRD2, with risperidone-induced hyperprolactinemia have been found in children with ASD, but such genetic associations have not been found directly for aripiprazole in ASD. This evidence concerns the gene DRD2 and hyperprolactinemia.